TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCTS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.10 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 MARKET OVERVIEW
4.1 DRIVERS
4.1.1 INCREASING PREVALENCE OF PERSISTENT CORNEAL EPITHELIAL DEFECTS AND OTHER RELATED COMPLICATIONS
4.1.2 RISING CASES OF EYE SURGERIES AND USAGE OF CONTACT LENSES
4.1.3 GROWING AGEING POPULATION AUGMENTING TOWARDS THE PCED CONDITION
4.1.4 INCREASE IN MECHANICAL TRAUMAS CASES
4.2 RESTRAINT
4.2.1 STRINGENT REGULATORY PROCEDURES
4.2.2 UNMET MEDICAL NEEDS FOR THE TREATMENT OF PCED
4.2.3 HIGH COST OF PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENTS
4.3 OPPORTUNITIES
4.3.1 DEVELOPMENT OF NOVEL THERAPEUTICS
4.3.2 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE
4.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
4.3.4 EMERGING MARKET ECONOMY CREATES SIGNIFICANT OPPORTUNITIES
4.4 CHALLENGES
4.4.1 DEPENDENCY ON THIRD PARTY SUPPLIERS
5 PREMIUM INSIGHTS
6 EPIDEMIOLOGY
7 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY CLINICAL CAUSES
7.1 OVERVIEW
7.2 INFLAMMATORY DISEASE
7.3 NEUROTROPHIC KERATITIS (NK)
7.4 EPITHELIAL/LIMBAL STEM CELL DEFICIENCY
7.5 OTHERS
8 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 DEVICES
8.2.1 BANDAGE CONTACT LENS
8.2.2 AMNIOTIC MEMBRANE GRAFTS
8.2.3 PUNCTAL PLUGS
8.2.3.1 SILICONE PLUG
8.2.3.2 COLLAGEN PLUGS
8.2.4 CORNEAL TRANSPLANTS
8.2.4.1 KERATOPLASTY
8.2.4.2 KERATOPROSTHESIS
8.3 MEDICATION
8.3.1 DRUG TYPE
8.3.1.1 LUBRICANTS
8.3.1.2 PROPHYLACTIC TOPICAL ANTIBIOTICS
8.3.1.2.1 POLYMIXIN B-TRIMETHOPRIM + FLUOROQUINOLONE
8.3.1.2.2 FLUOROQUINOLONE
8.3.1.3 TOPICAL OPHTHALMIC STEROIDS
8.3.1.4 AUTOLOGOUS SERUM TEARS/AUTOLOGOUS SERUM EYE DROPS
8.3.1.5 TETRACYCLINES
8.3.1.6 HUMAN NERVE GROWTH FACTOR (OXERVATE)
8.3.1.7 WOUND HEALING AGENTS
8.3.1.8 OTHERS
8.3.2 ROUTE OF ADMINISTRATION
8.3.2.1 TOPICAL
8.3.2.2 ORAL
9 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 HOMECARE
9.4 SPECIALTY CLINICS
9.5 OTHERS
10 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACIES
10.3 RETAIL PHARMACIES
10.4 ONLINE PHARMACIES
11 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, BY GEOGRAPHY
11.1 EUROPE
11.1.1 GERMANY
11.1.2 U.K.
11.1.3 FRANCE
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 RUSSIA
11.1.7 NETHERLANDS
11.1.8 SWITZERLAND
11.1.9 BELGIUM
11.1.10 TURKEY
11.1.11 AUSTRIA
11.1.12 IRELAND
11.1.13 NORWAY
11.1.14 HUNGARY
11.1.15 POLAND
11.1.16 LITHUANIA
11.1.17 REST OF EUROPE
12 EUROPE PERSISTENT CORNEAL EPITHELIAL DEFECTS TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
13 COMPANY PROFILE
13.1 JOHNSON & JOHNSON SERVICES, INC.
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 ALLERGAN
13.2.1 COMPANY SNAPSHOT
13.2.2 REVENUE ANALYSIS
13.2.3 COMPANY SHARE ANALYSIS
13.2.4 PRODUCT PORTFOLIO
13.2.5 RECENT DEVELOPMENT
13.3 BIO-TISSUE (A SUBSIDIARY OF TISSUETECH, INC.)
13.3.1 COMPANY SNAPSHOT
13.3.2 COMPANY SHARE ANALYSIS
13.3.3 PRODUCT PORTFOLIO
13.3.4 RECENT DEVELOPMENTS
13.4 LABORATOIRES THÉA S.A.S
13.4.1 COMPANY SNAPSHOT
13.4.2 COMPANY SHARE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENT
13.5 NOVARTIS AG
13.5.1 COMPANY SNAPSHOT
13.5.2 REVENUE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENT
13.6 BAUSCH HEALTH
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENT
?
13.7 INTEGRA LIFESCIENCES CORPORATION
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENT
13.8 ALMIRALL, S.A
13.8.1 COMPANY SNAPSHOT
13.8.2 REVENUE ANALYSIS
13.8.3 PRODUCT PORTFOLIO
13.8.4 RECENT DEVELOPMENT
13.9 DOMPÉ FARMACEUTICI S.P.A.
13.9.1 COMPANY SNAPSHOT
13.9.2 PRODUCT PORTFOLIO
13.9.3 RECENT DEVELOPMENTS
13.10 HUNT VALLEY PHARMALAB
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENT
13.11 I-MED PHARMA INC.
13.11.1 COMPANY SNAPSHOT
13.11.2 PRODUCT PORTFOLIO
13.11.3 RECENT DEVELOPMENT
13.12 KALA PHARMACEUTICALS
13.12.1 COMPANY SNAPSHOT
13.12.2 PRODUCT PORTFOLIO
13.12.3 RECENT DEVELOPMENTS
13.13 KATENA PRODUCTS. INC.
13.13.1 COMPANY SNAPSHOT
13.13.2 PRODUCT PORTFOLIO
13.13.3 RECENT DEVELOPMENTS
13.14 NEXT BIOSCIENCES
13.14.1 COMPANY SNAPSHOT
13.14.2 PRODUCT PORTFOLIO
13.14.3 RECENT DEVELOPMENT
13.15 OCULAR SCIENCE, INC.
13.15.1 COMPANY SNAPSHOT
13.15.2 PRODUCT PORTFOLIO
13.15.3 RECENT DEVELOPMENT
?
13.16 SKYE BIOLOGICS INC.
13.16.1 COMPANY SNAPSHOT
13.16.2 PRODUCT PORTFOLIO
13.16.3 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 RELATED REPORTS